PLGA-Based Nano-Adjuvant Enhances Mucosal and Systemic Immunity in Chicks

Study Background and Research Question

The persistent challenge posed by the H9N2 subtype avian influenza virus (AIV) in poultry has driven the search for more effective vaccine strategies. H9N2 AIV, a low-pathogenicity virus, continues to threaten the global poultry industry by evading conventional vaccine approaches. The virus primarily invades hosts via the respiratory and digestive tracts and is shed through feces, facilitating rapid dissemination. While traditional inactivated and live attenuated vaccines can elicit strong humoral and cellular responses, they frequently fail to induce sufficient mucosal immunity—the first line of defense in the gut, where initial viral colonization occurs. The reference study, published in Poultry Science, addresses this critical gap by developing a novel nano-adjuvant designed to enhance mucosal and systemic vaccine-induced immunity in chicks.

Key Innovation from the Reference Study

The principal innovation described in the study is the design and application of a multiple-immune-regulatory adjuvant, termed PEI-LSP-RA-PLGA. This adjuvant leverages a double-layer nanoparticle system based on poly(lactic-co-glycolic acid) (PLGA), a biodegradable polymer recognized for its safety and compatibility in biomedical applications. By encapsulating Lagenaria siceraria (Molina) Standl. polysaccharide (LSP) and retinoic acid (RA) within PLGA nanoparticles and further modifying their surface with polyethylenimine (PEI), the researchers produced particles with enhanced intestinal targeting, sustained antigen release, and the capacity to stimulate both mucosal (IgA) and systemic (IgG) immune responses. This approach directly addresses the limitations of existing adjuvants, which often lack the ability to elicit robust mucosal immunity.

Methods and Experimental Design Insights

The nano-adjuvant was prepared using a double-layer (water-in-oil-in-water; W1/O/W2) nanoparticle technique, enabling the co-encapsulation of hydrophobic (RA) and hydrophilic (LSP) agents. The resulting PEI-LSP-RA-PLGA nanoparticles exhibited a uniform size of approximately 200 nm and a positive zeta potential of 13 mV, contributing to their stability and cellular uptake. Key aspects of the experimental design included:

• Encapsulation efficiency and sustained-release properties were characterized, revealing antigen release for up to 21 days post-injection.
• Chicks were immunized with the inactivated H9N2 vaccine formulated with PEI-LSP-RA-PLGA nanoparticles.
• Serum IgG and intestinal IgA responses, cytokine secretion, immune organ development, and small intestine morphology were quantitatively assessed post-vaccination.
• In vivo fluorescence imaging was employed to track nanoparticle distribution, confirm intestinal targeting, and assess antigen persistence at the injection site.
• Sequencing and mechanistic studies elucidated the involvement of CCR9/CCR6 chemokine signaling and downstream immune pathways.

Protocol Parameters

• PLGA nanoparticle preparation: Double emulsion (W1/O/W2) method for co-encapsulation of LSP (hydrophilic) and RA (hydrophobic) agents.
• Particle characterization: Target size ~200 nm; zeta potential +13 mV; stability and sustained antigen release confirmed for 21 days.
• Immunization schedule: Single or repeated doses using the formulated inactivated H9N2 vaccine; control groups included non-adjuvanted and commercial adjuvant formulations.
• Antibody quantification: Serum IgG and intestinal IgA measured by ELISA at defined time points post-immunization.
• In vivo tracking: Fluorescent dye labeling (see below) for nanoparticle biodistribution studies via live imaging.
• Molecular pathway interrogation: Analysis of CCR9/CCR6 signaling, Toll-like receptor pathway, NOD-like receptor pathway, and IgA production networks using gene expression profiling and confirmatory assays.

Core Findings and Why They Matter

The study demonstrated that PEI-LSP-RA-PLGA nanoparticles substantially outperformed control adjuvants in multiple immunological metrics:

• Serum IgG antibody levels increased by 132.83% compared to controls, indicating strong systemic immunity.
• Intestinal IgA antibody levels rose by 115.12%, signifying potent mucosal immune induction (reference study).
• Enhanced secretion of immunoregulatory cytokines and improved development of immune organs and intestinal structure were observed.
• Fluorescence imaging confirmed that the nanoparticles provided long-term antigen retention at the injection site and effective intestinal targeting, leading to increased IgA+ cell counts in the gut.
• Mechanistically, CCR9 and CCR6 signaling pathways (via chemokines CCL20 and CCL25) mediated the intestinal targeting, while Toll-like and NOD-like receptor pathways supported mucosal immune activation and IgA production.

Collectively, these results highlight the potential of the PEI-LSP-RA-PLGA system to bridge the gap between systemic and mucosal immunity, enabling more effective control of enteric viruses like H9N2 AIV in poultry.

Comparison with Existing Internal Articles

Fluorescence imaging was instrumental in tracking the biodistribution and persistence of the nano-adjuvant. Recent internal articles, such as "Sulfo-Cy5 Carboxylic Acid: Advancing Fluorescence Imaging..." and "Sulfo-Cy5 Carboxylic Acid: Advancing Translational Imaging", have emphasized the importance of using sulfonated hydrophilic fluorescent dyes like Sulfo-Cy5 carboxylic acid for high-sensitivity imaging in biological systems. These resources underscore the advantages of dyes with high water solubility and reduced fluorescence quenching, particularly in protein and peptide labeling workflows. The reference study's use of advanced fluorescence imaging aligns with these best practices, demonstrating how robust labeling tools enable precise tracking of nanoformulations in vivo and facilitate mechanistic insights into vaccine adjuvant action. Furthermore, the internal article on translational immunology (see here) provides broader context for the application of hydrophilic dyes in validating mucosal immunity mechanisms, as exemplified by the current study's focus on IgA+ cell distribution.

Limitations and Transferability

Despite the promising results, the study has several limitations that warrant consideration:

• All experiments were performed in chick models; transferability to other avian species or mammals requires further validation.
• While the nano-adjuvant system showed significant efficacy against H9N2 AIV, its performance against other pathogens remains to be tested.
• Long-term safety, manufacturing scalability, and regulatory considerations must be addressed before field deployment.

Nevertheless, the mechanistic insights—particularly the combination of sustained antigen release, intestinal targeting, and coordinated immune pathway activation—may inform the rational design of next-generation nano-adjuvants for both veterinary and potentially human vaccines, pending further cross-species studies.

Research Support Resources

For researchers seeking to replicate or extend in vivo imaging workflows described in this study, Sulfo-Cy5 carboxylic acid (SKU A8137) from APExBIO offers a sulfonated, hydrophilic fluorescent dye with high water solubility and reduced fluorescence quenching. This reagent is well-suited for protein and peptide labeling in aqueous environments, supporting high-fidelity tracking of nanoparticles and immune targets in fluorescence imaging experiments. For workflows that require covalent labeling, the pre-activated sulfo-Cy5 NHS ester variant is recommended. Researchers are encouraged to consult protocol guidance and internal literature for best practices in integrating such fluorescent dyes into advanced immunological studies.